Evaluation of outcomes for psychosis and epilepsy treatment delivered by primary health care workers in Nepal: a cohort study

Table 2 Clinical outcome summary scores from clinician interview for patients with psychosis

	Program (n = 53)		Control (n = 21)		ANCOVA		Full cohort (n = 74)
	Mean	SD	Mean	(SD)	Effect size F, partial eta²	P-value*	Mean	(SD)	Effect size Z, r	P-value**
PANSS positive and negative					< 0.01, < 0.01	0.96			6.87, 0.80	< 0.0001
Baseline	25.5	12.1	24.9	11.9			25.3	− 12
end point	7.9	7.4	10.3	12.2			8.6	− 9
Δ score	− 17.6	12.5	− 14.6	14.1			− 16.8	− 12.9
PANSS positive					1.22, 0.02	0.22			6.87, 0.80	< 0.0001
Baseline	11.6	6.8	13.1	5.7			12	6.5
end point	2.7	3.3	3.7	4.6			3	4.6
Δ score	− 8.9	7.7	− 9.3	7.5			− 9	7.5
PANSS negative					2.16, 0.03	0.69			6.42, 0.75	< 0.0001
Baseline	13.9	7.3	11.8	7.4			13.3	7.4
end point	5.2	5.3	6.6	7.7			5.6	6.1
Δ score	− 8.7	7	− 5.2	8			− 7.7	7.4
HAM-D					0.02, < 0.01	0.27			6.02, 0.70	< 0.0001
Baseline	15.6	7.2	16.3	7.8			15.8	7.3
end point	7.7	4.5	8.0	6.7			7.8	6.7
Δ score	− 7.8	8.0	− 8.4	11.3			− 8.0	9.0

HAM-D Hamilton Depression Scale, PANSS positive and negative syndrome scale
* P-value taken from ANCOVA (analysis of covariance) for each scale comparing program vs. control scores at end point, adjusted for baseline score
** P-value from Wilcoxon Signed-Rank Test comparing baseline to end point scores (full cohort)

ISSN: 1752-4458